Cell and Gene Therapy Market to grow at a CAGR of 18.12% during 2025 to 2035; Driven by Rising Prevalence of Genetic Disorders and Increasing Investment in Advanced Therapeutic Development

Cell and Gene Therapy Market Highlights

The Cell and Gene Therapy Market was estimated at 15.01 USD Billion in 2024. The Cell and Gene Therapy industry is projected to grow from 17.73 USD Billion in 2025 to 93.76 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 18.12% during the forecast period 2025 - 2035.

The global Cell and Gene Therapy Market is emerging due to the Increasing incidences of diseases such as cancer, cystic fibrosis, sickle cell anemia, and others and increasing approval for gene and cell therapy products. Additionally, the growing technological advancements and innovation will provide growth opportunities for the market in the future.

MRFR recognizes the following companies as the key players in the Global Cell and Gene Therapy Market - Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), Janssen Global Services (US).

Segment Analysis

The global Cell and Gene Therapy Market has been segmented based on Therapy Type and Application

Based on therapy type, the global cell & gene therapy market has been segmented into cell therapy and gene therapy. The cell therapy segment held the largest market share in 2024 and gene therapy is the fastest-growing segment during the forecast period i.e., 2025 -2035.

Gene therapy segment is further segmented into Autologous and Allogenic. The autologous segment dominated the market in 2024. Additionally, it is anticipated that during the forecast period, this segment will increase more quickly. Due to the widespread use of CAR-T treatments and their successful outcomes in the treatment of various malignancies and genetic abnormalities, the market is expected to rise.

The gene therapy segment is further segmented into Ex-vivo and In-vivo. The in vivo therapy segment held the largest market share in 2024, owing to increase in the adoption of in vivo gene therapies globally. As vivo gene therapy can reach multiple sites or organs throughout the body, it allows for systemic treatment. This is especially beneficial for diseases that affect multiple organ systems or have systemic manifestations, allowing for a more comprehensive therapeutic approach.

Based on application, the global cell & gene therapy market has been segmented into Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders, and Others. The cancer segment held the largest market and is the fastest growing segment during the forecast period, owing to increase in prevalence of cancer, rise in development of gene and cell therapy drugs specific to oncology. 

Advances in gene editing technologies such as CRISPER-CAS9, TALEN, and zinc finger nucleases, enable precise modifications of gene in immune cells to enhance their anti-cancer properties. These technologies can be used to knock out the genes that inhibit immune responses or to introduce genes that enhance cytotoxicity against cancer cells. For instance, in 2022, the US Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg) in December 2022, new long-term follow up data has been revealed.

Regional Analysis

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

The Cell and Gene Therapy Market shows a robust growth trajectory within its regional segmentation. In 2024, North America is projected to hold a substantial market value of 4.5 USD Billion, expected to surge to 16.0 USD billion by 2035, reflecting its majority holding in the sector due to advanced healthcare systems and substantial Research and Development investments.

Europe follows with a valuation of 3.0 USD Billion in 2024, anticipated to grow to 10.5 USD billion by 2035, driven by strong regulatory frameworks and increased funding for biotechnological innovations.Meanwhile, South America is relatively smaller, valued at 0.5 USD Billion in 2024; however, its growth potential to 2.0 USD billion by 2035 cannot be overlooked, as it seeks to enhance its healthcare infrastructure.

The Asia Pacific region, a rising player, recorded a value of 1.5 USD billion in 2024, projected to reach 6.5 USD billion by 2035, propelled by increasing patient populations and demand for advanced therapies.

Key Findings of the Study

• North America remains the largest market for cell and gene therapies, driven by robust healthcare infrastructure and investment.


• Asia-Pacific is emerging as the fastest-growing region, fueled by increasing healthcare expenditure and a rising patient population.


• Cell therapy continues to dominate the market, while gene therapy is rapidly gaining traction as the fastest-growing segment.


• Key market drivers include the rising prevalence of genetic disorders and advancements in gene editing technologies, which are shaping the future of therapeutic options.